AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05999292 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-R8760 injection at pre-defined dose levels
Description: PET/CT imaging at predefined timepoints
Study NCT05999292 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-R8760 injection
Description: PET/CT imaging at a single timepoint
Study NCT02211287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Comfort Care at the End of Life for Persons with Dementia'
Description: A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
Study NCT02211287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project Nurse - ACP Facilitator
Description: A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
Study NCT06552637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Diaphragmatic Stimulation
Description: Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
Study NCT06552637 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synchronized Diaphragmatic Stimulation
Description: Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
Study NCT04911361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
Study NCT04911361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
Study NCT04811495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
Study NCT05021146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care and topical essential copaiba oil
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
Study NCT05021146 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care and placebo treatment
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
Study NCT05021146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
Study NCT05984602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
Study NCT05984602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
Study NCT05984602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: 125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
Study NCT05984602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
Study NCT04896281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine-free milk
Description: Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
Study NCT05806450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
Study NCT05806450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: Psychoeducation about basic sleep structure and sleep hygiene
Study NCT06251856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lymphedema education program
Description: On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
Study NCT05930210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F703 GEL
Description: Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
Study NCT05930210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENERGI-F703 matched vehicle
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Study NCT06538610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter monitor
Description: Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).~Holter monitor to be worn for approximately 46-48 hours.
Study NCT04738123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
Study NCT04738123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study NCT05731726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplilumab
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w.~For the timing of serplulimab, there is a subgroup developed, all enrolled patients will be divided into 2 subgroups in 1:1 ratio, the fasting group and the control group. For the fasting group patients, fasting starts from 8 p.m. the day before treatment and concludes at 12 p.m. on the treatment day, water is allowed. For the control group patients, they have meals according to their habits.
Study NCT05001243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac
Description: PBOHB to improve uncorrected near vision in healthy presbyopic patients
Study NCT05001243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Hydrochloride
Description: Apply in the fellow eye
Study NCT05001243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Apply in the fellow eye
Study NCT04951934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmoLED
Description: This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
Study NCT05731726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT05731726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT04951934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging.
Study NCT04951934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging.
Study NCT05651464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycine
Description: Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
Study NCT05731726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celebrex
Study NCT06248216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relievrx
Description: The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
Study NCT06248216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Audio Mp4
Description: Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
Study NCT05818774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning
Description: Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement
Study NCT05818774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae
Description: Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets.
Study NCT06372444 — intervention group
Intervention type: RADIATION
Intervention: Positron emission tomography (PET)
Description: Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
Study NCT05949177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure and Mindfulness Meditation
Description: Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.
Study NCT05949177 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
Study NCT05566795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Oral type II RAF kinase inhibitor
Study NCT05566795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapeutic Agent
Description: Intravenous solution for injection
Study NCT04948697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: 900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Study NCT04948697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Study NCT06067165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POET feeling
Description: POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961).~POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions.
Study NCT06067165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends. The parent component will include educative material and self reflection in how to support their adolescent.
Study NCT06382532 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Niacin skin reaction test
Description: Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
Study NCT05031585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roncoliv
Description: The medical device with nasal spray solution should be used 1 time a day, before bedtime, for 30 days.
Study NCT05031585 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The medical device with placebo should be used 1 time a day, before bedtime, for 30 days.
Study NCT05814731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-BUCY2
Description: Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
Study NCT05814731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUCY2
Description: Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
Study NCT00929461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipovenoes® 10% and Omegaven®,
Description: All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
Study NCT05325827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided high fascia iliaca compartment block
Description: H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
Study NCT04841837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: limit daily food intake to a period of 10 hours
Study NCT05573958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Rivaroxaban 2.5 mg oral tablet will be administered twice daily
Study NCT05573958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel tablet
Description: Clopidogrel 75 mg once daily orally
Study NCT05573958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Clopidogrel 75 mg once daily orally
Study NCT05573958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin tablet
Description: Aspirin 81 mg tablet once daily
Study NCT05573958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Aspirin 81 mg tablet once daily
Study NCT05164458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 308 injection
Description: IBI308 IV 200mg Q3W Day1
Study NCT05105997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone/ Erector Spinae Plane Block
Description: Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
Study NCT05105997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
Study NCT05888857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
Study NCT04336033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
Study NCT04336033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
Study NCT04336033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Renal Diet App
Description: Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
Study NCT04336033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Printed Nutrition Pamphlet
Description: After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions.
Study NCT05624073 — intervention group
Intervention type: DEVICE
Intervention: Air-QTM Blocker
Description: The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes